SCHEMBL4009747

SCHEMBL4009747

O=C(CC1CC1)Nc1ccc(N2CCC[C@H](NC(=O)N3C4CCC3CC(O)C4)C2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.45
ALDH1A1 P00352 7/20 0.44
GAA P10253 6/20 0.44
KMT2A Q03164 5/20 0.44
KDM4E B2RXH2 4/20 0.44
MEN1 O00255 4/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
LMNA P02545 2/20 0.44
GFER P55789 2/20 0.44
NAMPT P43490 4/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
HRH3 Q9Y5N1 2/20 0.39
MAPT P10636 5/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HTT P42858 1/20 0.38
RAD52 P43351 3/20 0.38
MAPK1 P28482 2/20 0.38
POLB P06746 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5950970 1.00 CNR1 (0.45) CNR1ALDH1A1GAAKMT2AKDM4E
SCHEMBL4138489 0.87 CNR1 (0.51) CNR1ALDH1A1GAAKMT2AKDM4E
SCHEMBL4138485 0.87 CNR1 (0.51) CNR1ALDH1A1GAAKMT2AKDM4E
SCHEMBL4004043 0.81 CNR1 (0.41) CNR1ALDH1A1GAAKMT2AKDM4E
SCHEMBL4003351 0.81 POLB (0.49) CNR1ALDH1A1KDM4ELMNANPC1
SCHEMBL5950786 0.81 CNR1 (0.41) CNR1ALDH1A1GAAKMT2AKDM4E
SCHEMBL4003357 0.81 POLB (0.49) CNR1ALDH1A1KDM4ELMNANPC1
SCHEMBL5950313 0.81 CNR1 (0.53) CNR1ALDH1A1GAAKMT2AMEN1
SCHEMBL4003634 0.81 NOTUM (0.46) CNR1KMT2AMEN1POLBNPSR1
SCHEMBL5950661 0.81 NOTUM (0.46) CNR1KMT2AMEN1POLBNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP claimed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP claimed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US claimed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO claimed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122197-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 CNR1 516/4885ALDH1A1 311/4885GAA 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.